BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) – Research analysts at Leerink Partnrs raised their FY2023 EPS estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($3.80) per share for the year, up […]
ATTRibute-CM results also demonstrated rapid clinical benefit on the composite endpoint of all-cause mortality (ACM) and CVH in patients treated with acoramidis, with time-to-first event Kaplan-Meier curves separating at month 3 and continuing to diverge steadily through Month 30